ImpactRx gobbles up TargetRx

ImpactRx, which measures the impact of promotion on prescriber behavior, said it acquired 100% of TargetRx, a pharma sales and marketing effectiveness firm. 

Terms were not disclosed, but a source familiar with the transaction estimated its size at $5-10 million.

Known as ImpactRx, the combined company will be led by new ImpactRx president and CEO Gregory Ellis, who recently replaced Richard Altus in that role. (See p. 55 for a profile.)

Since 1999, TargetRx has been providing pharma and biotech companies with insight into the drivers of both product choice and brand adoption. But it had struggled in the last year from customer and employee turnover. 

ImpactRx is part of private equity firm Symphony Technology Group, which in April acquired a majority interest for an undisclosed sum. Merck Capital Ventures, the venture capital arm of Merck, also maintains a stake.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.